Your browser is no longer supported. Please, upgrade your browser.
ORGO Organogenesis Holdings Inc. daily Stock Chart
Organogenesis Holdings Inc.
Index- P/E- EPS (ttm)-1.86 Insider Own0.10% Shs Outstand90.58M Perf Week-0.39%
Market Cap462.86M Forward P/E- EPS next Y-0.48 Insider Trans- Shs Float26.67M Perf Month-28.53%
Income-106.70M PEG- EPS next Q-0.09 Inst Own21.10% Short Float1.04% Perf Quarter1.59%
Sales379.80M P/S1.22 EPS this Y-96.80% Inst Trans17.37% Short Ratio1.98 Perf Half Y-30.00%
Book/sh0.14 P/B36.50 EPS next Y2.00% ROA- Target Price10.67 Perf Year-49.51%
Cash/sh0.25 P/C20.12 EPS next 5Y- ROE- 52W Range3.56 - 310.90 Perf YTD-49.66%
Dividend- P/FCF- EPS past 5Y- ROI-50.60% 52W High-98.36% Beta-
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin85.40% 52W Low43.54% ATR0.46
Employees700 Current Ratio1.40 Sales Q/Q26.60% Oper. Margin- RSI (14)35.65 Volatility6.95% 7.61%
OptionableNo Debt/Eq7.88 EPS Q/Q-124.60% Profit Margin- Rel Volume3.59 Prev Close4.81
ShortableNo LT Debt/Eq7.66 EarningsNov 12 AMC Payout- Avg Volume140.65K Price5.11
Recom1.30 SMA20-19.29% SMA50-25.26% SMA200-24.67% Volume505,307 Change6.24%
Aug-26-19Resumed Credit Suisse Outperform $9 → $10
May-02-19Initiated Credit Suisse Outperform $9
Apr-17-19Initiated Oppenheimer Outperform $11
Apr-11-19Initiated SunTrust Buy $11
Nov-21-19 10:04PM  Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock GlobeNewswire -16.28%
Nov-20-19 07:25AM  The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Benzinga -8.92%
Nov-19-19 04:01PM  Organogenesis Holdings Inc. Announces Proposed Public Offering of Class A Common Stock GlobeNewswire
Nov-12-19 04:05PM  Organogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results GlobeNewswire
Nov-11-19 11:22AM  Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet? Simply Wall St.
Oct-11-19 04:05PM  Latest Advanced Wound Care Research from Organogenesis Highlighted at SAWC Fall 2019 GlobeNewswire +5.87%
Oct-05-19 09:00AM  New ReNu® Data from Organogenesis Highlighted at ICRS 2019 World Congress GlobeNewswire
Sep-17-19 07:30AM  Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2019 Financial Results on November 12, 2019 GlobeNewswire
Sep-06-19 04:06PM  Largest Insider Trades of the Week +16.38%
09:00AM  MEDIA ALERT: Organogenesis Holdings Inc. (Nasdaq: ORGO) to Ring the Nasdaq Stock Market Closing Bell GlobeNewswire
08:00AM  Organogenesis Announces Annual College Scholarship Award Winner GlobeNewswire
Aug-19-19 04:57PM  Organogenesis Announces Completion of Exchange Offer and Plan to Exchange Remaining Outstanding Public Warrants GlobeNewswire +7.59%
Aug-09-19 01:24PM  Organogenesis Holdings Inc. (ORGO) Q2 2019 Earnings Call Transcript Motley Fool
07:00AM  Organogenesis Holdings Inc. Reports Second Quarter and First Half 2019 Financial Results GlobeNewswire
Jul-22-19 04:15PM  Organogenesis Holdings Commences Offer to Exchange Class A Common Stock for any and all Outstanding Public Warrants and Consent Solicitation GlobeNewswire
Jul-08-19 08:00AM  Organogenesis Announces 2019 Sponsorship of American Podiatric Medical Association Educational Programs and Annual Scientific Meeting GlobeNewswire
Jul-01-19 07:30AM  Organogenesis Joins Russell 2000®, Russell 3000® and Russell Microcap® Indexes GlobeNewswire +5.26%
May-10-19 12:17PM  Organogenesis Holdings Inc. (ORGO) Q1 2019 Earnings Call Transcript Motley Fool
07:08AM  Organogenesis Holdings Inc. Reports First Quarter 2019 Financial Results GlobeNewswire
May-01-19 08:30AM  Organogenesis Receives Innovative Technology Contract from Vizient GlobeNewswire
Apr-30-19 08:30AM  Latest Wound Care Research from Organogenesis Highlighted at SAWC Spring 2019 GlobeNewswire
Apr-02-19 07:30AM  Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2019 Financial Results on May 10, 2019 GlobeNewswire
Apr-01-19 08:30AM  Organogenesis Compliant With Nasdaq Listing Criteria GlobeNewswire
Mar-18-19 04:05PM  Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results GlobeNewswire
Mar-14-19 04:05PM  Organogenesis Holdings Inc. Announces New $100 Million Credit Agreement with Silicon Valley Bank and MidCap Financial PR Newswire
Mar-12-19 09:00AM  Organogenesis Holdings Inc. Announces ReNu® Clinical Trial Results at AAOS 2019 Annual Meeting GlobeNewswire
Mar-11-19 07:30AM  Organogenesis Holdings Inc. to Present at Oppenheimers 29th Annual Healthcare Conference GlobeNewswire +38.08%
Mar-04-19 09:00AM  New Study Shows PuraPly® Antimicrobial Positively Impacts Course of Healing Across Variety of Wound Types GlobeNewswire
Feb-25-19 08:00AM  Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2018 Financial Results on March 18, 2019 GlobeNewswire
Jan-24-19 10:00AM  Organogenesis to Sponsor Jan. 30 Webinar, Chronic Wounds and Biofilms: Advancing Assessment and Treatment, Featuring Dr. Gregory Schultz GlobeNewswire -8.13%
Jan-07-19 05:54PM  Organogenesis Holdings Inc. Receives Positive Nasdaq Listing Determination PR Newswire
04:15PM  Nasdaq Scheduled Resumption in Organogenesis Holdings Inc. GlobeNewswire
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Avista Capital Managing MemberDirectorNov 26Buy5.006,000,00030,000,00024,975,165Nov 27 04:17 PM